GLP-1: A Hormone with Effects Far Beyond the Gut
Glucagon-like peptide-1 (GLP-1) was initially characterized as an incretin hormone — a gut-derived signal that enhances insulin secretion after eating. But research over the past decade has revealed that GLP-1 receptors are expressed throughout the body, including the heart, brain, liver, kidneys, and immune cells. This widespread receptor distribution has opened research into GLP-1 receptor agonists like semaglutide and tirzepatide far beyond their metabolic origins.
Published research now encompasses cardiovascular protection, neuroprotection, liver disease, kidney function, and anti-inflammatory effects. This article reviews the evidence for each of these research areas.
Cardiovascular Research
The SUSTAIN-6 and SELECT Trials
Marso et al. (2016) published the SUSTAIN-6 trial in the New England Journal of Medicine, demonstrating that semaglutide reduced major adverse cardiovascular events (MACE) — a composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke — by 26% compared to placebo in patients with type 2 diabetes and high cardiovascular risk.
The SELECT trial (Lincoff et al., 2023) extended these findings to individuals without diabetes, showing a 20% reduction in MACE with semaglutide 2.4 mg. This result was significant because it demonstrated cardiovascular benefit independent of glucose-lowering effects, suggesting direct cardioprotective mechanisms.
Proposed Cardiovascular Mechanisms
The cardiovascular effects of GLP-1 receptor agonists appear to involve multiple pathways:
- Endothelial function: GLP-1R activation improves endothelial-dependent vasodilation through NO signaling (Nyström et al., 2004)
- Atherosclerosis: Reduced macrophage foam cell formation and plaque inflammation in preclinical models
- Blood pressure: Modest reductions in systolic blood pressure, possibly through natriuretic effects
- Lipid metabolism: Reductions in postprandial triglycerides and improvements in lipoprotein profiles
- Inflammation: Reduced C-reactive protein and other inflammatory biomarkers
Neuroprotection Research
GLP-1 Receptors in the Brain
GLP-1 receptors are expressed in multiple brain regions, including the hippocampus, hypothalamus, cortex, and brainstem. Endogenous GLP-1 is produced both by intestinal L-cells and by neurons in the nucleus tractus solitarius (NTS), which project to these brain areas (Holst, 2007).
Alzheimer's Disease Research
Hölscher (2022) published a review in the Journal of Alzheimer's Disease compiling preclinical evidence that GLP-1 receptor agonists reduce amyloid-beta plaque burden, decrease tau phosphorylation, improve synaptic plasticity, and enhance memory in rodent models of Alzheimer's disease.
The ELAD trial (Edison et al., 2021) was among the first human studies to examine liraglutide (a GLP-1 agonist) in Alzheimer's patients. While preliminary and small, the study reported differences in cerebral glucose metabolism (measured by FDG-PET) between treatment and control groups over 12 months.
Parkinson's Disease Research
Athauda et al. (2017) published results from the Exenatide-PD trial in The Lancet, reporting that exenatide (a GLP-1 agonist) was associated with sustained improvements in motor function in Parkinson's disease patients compared to placebo. The effects persisted 12 weeks after drug washout, suggesting a disease-modifying mechanism rather than symptomatic relief.
Proposed neuroprotective mechanisms include:
- Reduction of neuroinflammation through modulation of microglial activation
- Enhancement of mitochondrial function in neurons
- Activation of BDNF-dependent neuroplasticity pathways
- Protection against excitotoxicity (glutamate-mediated neuronal damage)
Liver and Hepatoprotective Research
MASH/NAFLD Research
Metabolic dysfunction-associated steatohepatitis (MASH, previously NASH) is characterized by liver fat accumulation, inflammation, and progressive fibrosis. GLP-1 receptor agonists have emerged as a major research focus in this area.
Newsome et al. (2021) published the LEAN trial results showing that semaglutide 0.4 mg daily resolved MASH in 59% of patients versus 17% with placebo, as measured by liver biopsy. The ESSENCE trial (2024) subsequently demonstrated fibrosis improvement alongside MASH resolution.
The liver-specific effects of GLP-1 agonists include:
- Reduced hepatic de novo lipogenesis (new fat production in the liver)
- Decreased liver inflammation (reduced NAS score components)
- Improved insulin sensitivity in hepatocytes
- Potential direct anti-fibrotic effects through hepatic stellate cell modulation
Kidney Research
The FLOW trial (Perkovic et al., 2024) demonstrated that semaglutide reduced the risk of kidney disease progression by 24% in patients with type 2 diabetes and chronic kidney disease. Kidney-protective mechanisms may include:
- Reduced glomerular hyperfiltration through tubuloglomerular feedback modulation
- Decreased renal inflammation and oxidative stress
- Improved glycemic and blood pressure control
- Direct GLP-1 receptor-mediated effects on mesangial and tubular cells
Anti-Inflammatory Research
Hogan et al. (2014) demonstrated that GLP-1 receptor agonists reduce inflammatory cytokine production from human macrophages and T cells. This immunomodulatory effect extends beyond metabolic inflammation to systemic inflammatory pathways, and has generated interest in GLP-1 agonist research for autoimmune and inflammatory conditions.
Tirzepatide: The Dual-Agonist Approach
Tirzepatide represents an evolution in incretin research — a single molecule that activates both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. Research suggests that GIP receptor activation contributes complementary effects including enhanced central appetite regulation and improved lipid metabolism (Frias et al., 2021).
Whether dual agonism provides advantages over selective GLP-1 agonism across all research contexts — cardiovascular, neurological, hepatic — remains an active area of investigation.
Research Implications
The expanding research profile of GLP-1 receptor agonists illustrates a broader principle in peptide biology: hormones rarely have single targets. GLP-1's distribution across cardiovascular, neural, hepatic, and renal tissue means that GLP-1 receptor agonists touch multiple organ systems simultaneously. Understanding these pleiotropic effects — and distinguishing direct receptor-mediated mechanisms from indirect metabolic improvements — continues to drive research in this rapidly growing field.
This article is for educational and informational purposes only. BeaCapra supplies research peptides for laboratory and research use. Nothing in this article constitutes medical advice.